NextCell

NextCell Pharma is a Swedish biopharmaceutical company specializing in the development of mesenchymal stem cell (MSC) therapies for autoimmune and inflammatory diseases. The company's core technology, ProTrans, is an off-the-shelf cell therapy platform that utilizes a proprietary selection algorithm to identify the most potent cells from umbilical cord tissue. Its lead clinical program is focused on preserving endogenous insulin production in patients with Type 1 Diabetes, with ongoing trials in both adults and children. Beyond its therapeutic pipeline, NextCell operates Cellaviva, Scandinavia's largest private stem cell bank, which offers umbilical cord blood and tissue banking services. The company is headquartered at the Karolinska Institutet Science Park and is listed on the Nasdaq First North Growth Market.